Alterations in binding site density of dopamine transporter in the striatum, orbitofrontal cortex, and amygdala in early Parkinson's disease: compartment analysis for beta-CFT binding with positron emission tomography
- PMID: 10319882
Alterations in binding site density of dopamine transporter in the striatum, orbitofrontal cortex, and amygdala in early Parkinson's disease: compartment analysis for beta-CFT binding with positron emission tomography
Abstract
We investigated changes in the kinetics in the binding of the dopamine transporter probe 2-beta-carbomethoxy-3beta-(4-[11C]fluorophenyl)tropane (beta-CFT) in living brain by compartmental analysis, using positron emission tomography in unmedicated patients with Parkinson's disease (PD) (Hoehn and Yahr stages I-II). With dynamic positron emission tomographic data from 90-minute acquisitions and metabolite-corrected arterial input functions, binding potentials (k3/k4) were calculated by using estimated rate constants (K1 - k4). In this analysis, the magnitude of the distribution volume (K1/k2) measured in the cerebellum, in which specific binding is negligible, was used as a constrained value for fitting in binding regions. Statistics showed that k3/k4 values in the striatum, the orbitofrontal cortex, and the amygdala were significantly lower in PD patients than in normal controls, whereas there were no differences in K1/k2 ratios and structural volumes between the groups. Correlation analysis showed that the putaminal and orbitofrontal binding levels were correlated positively with motor and mentation scores, respectively, of the Unified Parkinson's Disease Rating Scale. These results indicated that not only the striatal but also the orbitofrontal and amygdalar presynaptic dopaminergic functions were altered in early PD. The reductions in these mesocortical/mesolimbic functions might contribute to the mental and behavioral impairment observed in PD.
Similar articles
-
Presynaptic and postsynaptic dopaminergic binding densities in the nigrostriatal and mesocortical systems in early Parkinson's disease: a double-tracer positron emission tomography study.Ann Neurol. 1999 Nov;46(5):723-31. doi: 10.1002/1531-8249(199911)46:5<723::aid-ana7>3.0.co;2-r. Ann Neurol. 1999. PMID: 10553989
-
Changes in dopamine availability in the nigrostriatal and mesocortical dopaminergic systems by gait in Parkinson's disease.Brain. 2001 Apr;124(Pt 4):784-92. doi: 10.1093/brain/124.4.784. Brain. 2001. PMID: 11287377 Clinical Trial.
-
Positron emission tomographic imaging of the dopamine transporter with 11C-WIN 35,428 reveals marked declines in mild Parkinson's disease.Ann Neurol. 1993 Sep;34(3):423-31. doi: 10.1002/ana.410340331. Ann Neurol. 1993. PMID: 8363363
-
Imaging of the dopaminergic neurotransmission system using single-photon emission tomography and positron emission tomography in patients with parkinsonism.Eur J Nucl Med. 1999 Feb;26(2):171-82. doi: 10.1007/s002590050374. Eur J Nucl Med. 1999. PMID: 9933352 Review.
-
Single-photon emission tomography imaging of dopamine terminal innervation: a potential clinical tool in Parkinson's disease.Eur J Nucl Med. 1994 Jan;21(1):1-5. doi: 10.1007/BF00182298. Eur J Nucl Med. 1994. PMID: 8088279 Review. No abstract available.
Cited by
-
Dopamine modulates the response of the human amygdala: a study in Parkinson's disease.J Neurosci. 2002 Oct 15;22(20):9099-103. doi: 10.1523/JNEUROSCI.22-20-09099.2002. J Neurosci. 2002. PMID: 12388617 Free PMC article. Clinical Trial.
-
Can the Ability to Recognize Facial Emotions in Individuals With Neurodegenerative Disease be Improved? A Systematic Review and Meta-analysis.Cogn Behav Neurol. 2023 Dec 1;36(4):202-218. doi: 10.1097/WNN.0000000000000348. Cogn Behav Neurol. 2023. PMID: 37410880 Free PMC article.
-
In vivo mesolimbic D2/3 receptor binding predicts posttherapeutic clinical responses in restless legs syndrome: a positron emission tomography study.J Cereb Blood Flow Metab. 2012 Apr;32(4):654-62. doi: 10.1038/jcbfm.2011.201. Epub 2012 Jan 11. J Cereb Blood Flow Metab. 2012. PMID: 22234337 Free PMC article. Clinical Trial.
-
Neurotrophin receptor heterozygosity causes deficits in catecholaminergic innervation of amygdala and hippocampus in aged mice.J Neural Transm (Vienna). 2006 Dec;113(12):1829-36. doi: 10.1007/s00702-006-0498-2. Epub 2006 Jun 1. J Neural Transm (Vienna). 2006. PMID: 16736233
-
Decreased glutamic acid decarboxylase mRNA expression in prefrontal cortex in Parkinson's disease.Exp Neurol. 2010 Nov;226(1):207-17. doi: 10.1016/j.expneurol.2010.09.001. Epub 2010 Sep 9. Exp Neurol. 2010. PMID: 20832408 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical